Because metastatic NSCLC harboring KRAS G12C can be treated with KRAS‐targeting agents (e.g., sotorasib), the detection of KRAS subtypes using methods such as the Lung Cancer Compact Panel is essential for therapeutic decision‐making. Here, KRAS is linked to non-small cell lung carcinoma.